logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Gold rallied Thursday morning as presumptive GOP nominee Donald Trump proclaimed himself a "low interest rate person" who would push for new leadership at the Federal Reserve. Trump said he would not reappoint current Fed Chair Janet Yellen, who happens to be one of the architects of the Fed's current... Merck & Co. Inc.(MRK) reported a profit for the first-quarter that grew 18 percent from the prior year, while quarterly sales declined 1 percent. Adjusted earnings per share topped analysts' expectations, while quarterly sales missed their estimates. Shares of WM Morrison Supermarkets Plc were gaining more than 4 percent in the early Thursday morning trading as it reported 0.7 percent increase in first-quarter like-for-like sales excluding fuel. LFL sales were up 1.2 percent, including fuel.
comments powered by Disqus
Follow RTT